Choose Your Country or Region

Almonertinib (HS-10296)

Name: Almonertinib (HS-10296)
Brand: Selleck Chemicals
SKU: S8817
Rating: 5 (1 reviews)

Synonyms: Aumolertinib

Catalog No.S8817 Purity:99.98%

Almonertinib (HS-10296) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.

Almonertinib (HS-10296) Chemical Structure

CAS No. 1899921-05-1

Purity & Quality Control

Batch: S881701 DMSO]100 mg/mL]false]Ethanol]6 mg/mL]false]Water]Insoluble]false Purity: 99.98%

99.98

Almonertinib (HS-10296) Related Products

Related Targets	EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR	Click to Expand
Related Products	AG-490 AG-1478 Canertinib (CI-1033) Rociletinib (CO-1686) WZ4002 Genistein Poziotinib PD153035 PD153035 HCl Allitinib tosylate AEE788 (NVP-AEE788) Pelitinib (EKB-569) Canertinib dihydrochloride Varlitinib Icotinib (BPI-2009H) Nazartinib (EGF816) NSC228155 PD168393 Olmutinib (BI 1482694) Zorifertinib (AZD3759) AZ5104 Lazertinib CL-387785 (EKI-785) TAK-285 Daphnetin Pyrotinib dimaleate Alflutinib (Furmonertinib) mesylate EGFR Inhibitor Chrysophanic Acid Norcantharidin WZ8040 Butein Cyasterone Avitinib (Abivertinib) CNX-2006 MTX-211 Naquotinib(ASP8273) Tuxobertinib (BDTX-189) WZ3146 Sunvozertinib (DZD9008) Tyrphostin 9 EAI045 zipalertinib (TAS6417) AG-18	Click to Expand
Related Compound Libraries	Kinase Inhibitor Library Tyrosine Kinase Inhibitor Library PI3K/Akt Inhibitor Library Cell Cycle compound library Angiogenesis Related compound Library	Click to Expand

Signaling Pathway

EGFR Signaling Pathway

Biological Activity

Description

Almonertinib (HS-10296) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.

Targets

EGFR-sensitizing mutation ^[1]

EGFR-T790M resistance mutation ^[1]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04841811	Recruiting	Lung Cancer	Guangdong Association of Clinical Trials\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	June 20 2022	Phase 3
NCT04882345	Unknown status	Lung Cancer\|EGFR Gene Mutation	Shanghai Chest Hospital\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	July 15 2021	Phase 2
NCT04944069	Not yet recruiting	NSCLC\|Leptomeningeal Metastasis\|EGFR Activating Mutation	Second Affiliated Hospital of Nanchang University\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	July 2021	Not Applicable
NCT04870190	Not yet recruiting	NSCLC	Shanghai Chest Hospital	June 1 2021	Phase 3
NCT04354961	Recruiting	Pulmonary Adenosquamous Carcinoma	Fujian Cancer Hospital\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	May 7 2021	Phase 2
NCT04687241	Active not recruiting	Non-small Cell Lung Cancer	Jiangsu Hansoh Pharmaceutical Co. Ltd.	April 30 2021	Phase 3

References

[1] James Chih-Hsin Yang, et al. J Thorac Oncol . 2020 Sep 9;S1556-0864(20)30714-0.

Chemical Information & Solubility

Molecular Weight	525.64	Formula	C₃₀H₃₅N₇O₂
CAS No.	1899921-05-1	SDF	--
Smiles	CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (190.24 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 6 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):